c-Myc

sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM.

MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6?μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5?μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis.

Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation.

EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.

hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities.

10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects.

VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration.

IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes.

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.

RK-9123016 is a potent inhibitor of SIRT2.

WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c-Myc molecule glue degrader.

VPC-70063 is a potent Myc-Max inhibitor with an IC50 value of 8.9 μM for Myc-Max transcriptional activity inhibition.

MDEG-541 is a potent MYC-MAX degrader.

MYC-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) to MYC internal ribosome entry site (IRES).

MYC degrader 1 (compound A80.2HCl) is an orally available MYC degrader with antitumor activity.

MYC degrader 1 TFA is a MYC degrader that restores pRB1 protein activity and reduces MYC-dependent CDK4/6 resistance.

MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a K d of 4 μM for MYC and an IC 50 of 10 μM for topoisomerase IIα ( Topoisomerase II α ).

c-Myc NLS TFA is a non-canonical nuclear localization signal (NLS) derived from the oncoprotein c-Myc, with the sequence PAAKRVKLD and containing 3 basic amino acids.

DL78 is an effective anti-mitotic agent.

Q901 (CDK7-IN-21) TFA is a selective and potent CDK7 inhibitor with an IC 50 of 10 nM.

BRD4-IN-12 is a potent and orally active BRD4 inhibitor with an IC 50 of 7.9 nM.

ZX079 is a dual BRD4 and CBP PROTAC degrader with a BRD4 DC 50 value of 0.035 nM and a CBP DC 50 value of < 0.02 nM.

dIRF4-2 is a selective IRF4 PROTAC degrader with a DC 50 value of 2.2 μM.